Geode Capital Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-64,823
| Closed | -$254K | – | 4806 |
|
|
2023
Q3 | $254K | Buy |
64,823
+35,751
| +123% | +$244K | ﹤0.01% | 3883 |
|
|
2023
Q2 | $94.5K | Sell |
29,072
-1,362
| -4% | -$4.05K | ﹤0.01% | 4354 |
|
|
2023
Q1 | $110K | Buy |
30,434
+62
| +0.2% | +$957 | ﹤0.01% | 4309 |
|
|
2022
Q4 | $977K | Buy |
30,372
+1,048
| +4% | +$41.5K | ﹤0.01% | 3349 |
|
|
2022
Q3 | $1.23M | Buy |
29,324
+11,988
| +69% | +$548K | ﹤0.01% | 3285 |
|
|
2022
Q2 | $731K | Sell |
17,336
-9,960
| -36% | -$462K | ﹤0.01% | 3561 |
|
|
2022
Q1 | $1.85M | Buy |
27,296
+1,117
| +4% | +$93K | ﹤0.01% | 3293 |
|
|
2021
Q4 | $3.18M | Buy |
26,179
+143
| +0.5% | +$24.1K | ﹤0.01% | 3141 |
|
|
2021
Q3 | $3.67M | Buy |
26,036
+2,429
| +10% | +$481K | ﹤0.01% | 3094 |
|
|
2021
Q2 | $6.49M | Buy |
23,607
+4,320
| +22% | +$1.09M | ﹤0.01% | 2748 |
|
|
2021
Q1 | $4.13M | Buy |
19,287
+2,946
| +18% | +$814K | ﹤0.01% | 2884 |
|
|
2020
Q4 | $3.95M | Buy |
16,341
+5,978
| +58% | +$739K | ﹤0.01% | 2721 |
|
|
2020
Q3 | $1.09M | Buy |
10,363
+2,409
| +30% | +$219K | ﹤0.01% | 3181 |
|
|
2020
Q2 | $779K | Buy |
7,954
+882
| +12% | +$77.2K | ﹤0.01% | 3227 |
|
|
2020
Q1 | $531K | Buy |
7,072
+736
| +12% | +$70.1K | ﹤0.01% | 3258 |
|
|
2019
Q4 | $514K | Buy |
6,336
+377
| +6% | +$42.2K | ﹤0.01% | 3491 |
|
|
2019
Q3 | $726K | Buy |
5,959
+15
| +0.3% | +$2.06K | ﹤0.01% | 3351 |
|
|
2019
Q2 | $1.07M | Buy |
5,944
+821
| +16% | +$133K | ﹤0.01% | 3220 |
|
|
2019
Q1 | $819K | Buy |
5,123
+613
| +14% | +$121K | ﹤0.01% | 3242 |
|
|
2018
Q4 | $1.17M | Buy |
4,510
+1,930
| +75% | +$388K | ﹤0.01% | 3038 |
|
|
2018
Q3 | $628K | Buy |
2,580
+91
| +4% | +$23.8K | ﹤0.01% | 3380 |
|
|
2018
Q2 | $587K | Buy |
+2,489
| New | +$726K | ﹤0.01% | 3381 |
|
Other funds holding EVLO
Geode Capital Management's EVLO Position: Q4 2023 in Review
Geode Capital Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 64,823 shares — an estimated $254K sold.
Geode Capital Management first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $6.49M in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Geode Capital Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Geode Capital Management sold 64,823 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $254K.
- Geode Capital Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Geode Capital Management's Evelo Biosciences, Inc. Common Stock position peaked at $6.49M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Geode Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.